Close Menu

University of Colorado, Denver

Using 26 pediatric ependymoma patient samples, researchers sequenced 18,500 single cells to classify and analyze discrete neoplastic subpopulations.

The group is mailing pharmacogenetic information back to patients, with plans to deliver genetic disease risk and carrier screening results.

The team will use a combination of genomics, pathology, and computer modeling to identify potential new therapeutic targets of the disease.

CU Denver and UC San Francisco teams are independently performing whole-genome sequencing to find genes involved in reduced efficacy of a common bronchodilator drug.

In PNAS this week: DNA damage associated with e-cigarette exposure, inflammasome inhibition by OLT1177, and more.

The organizations in the consortium will identify, characterize, and catalog human biological molecules affected by physical activity in volunteer biosamples.

Vanderbilt University, the University of Colorado at Denver, Partners HealthCare, and the Montreal Heart Institute will use Illumina technology to analyze their biobank samples.

The new findings point towards creating different treatment strategies for combating the disease in old and young patient groups. 

The partners will evaluate whether circulating tumor DNA profiling has use for monitoring treatment response and relapse in melanoma patients. 

Kauffman Foundation, MIT, BioAMPS, University of Colorado, Endo Pharma, Harvard, Galapagos, Flanders Institute of Biotechnology, and more …

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.